Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study

Kristina Ehrlich, Caroline Morbach, Theresa Reiter, Peter Ulrich Heuschmann, Anke Hannemann, Martin Fassnacht, Stefan Störk, Stefanie Hahner, Timo Deutschbein, Kristina Ehrlich, Caroline Morbach, Theresa Reiter, Peter Ulrich Heuschmann, Anke Hannemann, Martin Fassnacht, Stefan Störk, Stefanie Hahner, Timo Deutschbein

Abstract

Background: Endogenous Cushing's syndrome (CS) results in increased cardiovascular (CV) morbidity and mortality. So far, most studies focussed on distinct disease entities rather than the integrity of the CV system. We here describe the design of the Cardiovascular Status in Endogenous Cortisol Excess Study (CV-CORT-EX), a study aiming to comprehensively investigate the health status of patients with endogenous CS (with a particular focus on CV phenotypes, biochemical aspects, quality of life, and psychosocial status).

Method: A prospective non-interventional cohort study performed at a German tertiary referral centre. At the time of enrolment, patients will be categorised as: (1) newly diagnosed overt CS, (2) recurrent overt CS, (3) CS in remission, (4) presence of mild autonomous cortisol excess (MACE). The target cohorts will be n = 40 (groups 1 + 2), n = 80 (group 3), and n = 20 (group 4). Patients with overt CS at the time of enrolment will be followed for 12 months after remission (with re-evaluations after 6 and 12 months). At each visit, patients will undergo transthoracic echocardiography, cardiac magnetic resonance imaging, 24-h electrocardiogram, 24-h blood pressure measurement, and indirect evaluation of endothelial function. Furthermore, a standardised clinical investigation, an extensive biochemical workup, and a detailed assessment of quality of life and psychosocial status will be applied. Study results (e.g. cardiac morphology and function according to transthoracic echocardiography and cardiac magnetic resonance imaging; e.g. prevalence of CV risk factors) from patients with CS will be compared with matched controls without CS derived from two German population-based studies.

Discussion: CV-CORT-EX is designed to provide a comprehensive overview of the health status of patients with endogenous CS, mainly focussing on CV aspects, and the holistic changes following remission.

Trail registration: ClinicalTrials.gov ( https://ichgcp.net/clinical-trials-registry/NCT03880513" title="See in ClinicalTrials.gov">NCT03880513, registration date: 19 March 2019 (retrospectively registered). Protocol Date: 28 March 2014, Version 2.

Keywords: Cardiac magnetic resonance imaging; Cardiovascular status; Cushing’s syndrome; Echocardiography; Endogenous; Glucocorticoid excess; Hormones; Left ventricular hypertrophy; Metabolic profile; Quality of life.

Conflict of interest statement

The authors declare that no competing interests exist.

References

    1. Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117–123.
    1. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386:913–927. doi: 10.1016/S0140-6736(14)61375-1.
    1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism) Obes Res. 1994;2:486–508. doi: 10.1002/j.1550-8528.1994.tb00097.x.
    1. Nieman LK. Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015;173:33–38. doi: 10.1530/EJE-15-0464.
    1. Sugihara N, Shimizu M, Shimizu K, Ino H, Miyamori I, Nakabayashi H, et al. Disproportionate hypertrophy of the interventricular septum and its regression in Cushing’s syndrome. Report of three cases. Intern Med. 1992;31:407–413. doi: 10.2169/internalmedicine.31.407.
    1. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, et al. Assessment of left ventricular diastolic function and Tei index by tissue Doppler imaging in patients with Cushing’s syndrome. Echocardiography. 2008;25:182–190. doi: 10.1111/j.1540-8175.2007.00572.x.
    1. Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, et al. Patients with Cushing’s syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res. 2006;38:405–410. doi: 10.1055/s-2006-944545.
    1. Colao A, Pivonello R, Spiezia AF, Ferone D, Filippella M, Marzullo P, et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664–2672.
    1. Faggiano A, Pivonello R, Spiezia S, de Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88:2527–2533. doi: 10.1210/jc.2002-021558.
    1. Younge PA, Shmidt D, Wiles PG. Cushing’s syndrome: still a potential killing disease. J R Soc Med. 1995;88:174–175.
    1. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol. 2004;61:768–777. doi: 10.1111/j.1365-2265.2004.02168.x.
    1. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JHC, et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92:976–981. doi: 10.1210/jc.2006-2112.
    1. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol. 2011;75:436–442. doi: 10.1111/j.1365-2265.2011.04124.x.
    1. Hassan-Smith ZK, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA, et al. Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab. 2012;97:1194–1201. doi: 10.1210/jc.2011-2957.
    1. Etxabe J, Vazquez J. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol. 1994;40:479–484. doi: 10.1111/j.1365-2265.1994.tb02486.x.
    1. Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntali G, et al. Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 2016;4:569–576. doi: 10.1016/S2213-8587(16)30005-5.
    1. Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry. 1985;142:911–916. doi: 10.1176/ajp.142.8.911.
    1. Kelly WF. Psychiatric aspects of Cushing’s syndrome. QJM. 1996;89:543–551. doi: 10.1093/qjmed/89.7.543.
    1. Starkman MN. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin N Am. 2013;42:477–488. doi: 10.1016/j.ecl.2013.05.010.
    1. Wagner M, Tiffe T, Morbach C, Gelbrich G, Störk S, Heuschmann PU. Characteristics and course of heart failure stages A-B and determinants of progression - design and rationale of the STAAB cohort study. Eur J Prev Cardiol. 2017;24:468–479. doi: 10.1177/2047487316680693.
    1. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40:294–307. doi: 10.1093/ije/dyp394.
    1. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–1540. doi: 10.1210/jc.2008-0125.
    1. Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171:107–116. doi: 10.7326/M18-3630.
    1. Morbach C, Gelbrich G, Breunig M, Tiffe T, Wagner M, Heuschmann PU, et al. Impact of acquisition and interpretation on total inter-observer variability in echocardiography: results from the quality assurance program of the STAAB cohort study. Int J Card Imaging. 2018;34:1057–1065. doi: 10.1007/s10554-018-1315-3.
    1. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–2020. doi: 10.1056/NEJMoa0801891.
    1. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:85–94. doi: 10.1093/geronj/49.2.M85.
    1. Geiger J, Both S, Kircher S, Neumann M, Rosenwald A, Jahns R. Hospital-integrated biobanking as a service – the interdisciplinary Bank of Biomaterials and Data Wuerzburg (ibdw) Open J Bioresour. 2018;5:6. doi: 10.5334/ojb.38.
    1. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol. 2008;158:623–630. doi: 10.1530/EJE-07-0762.
    1. Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T. The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties. Clin Endocrinol. 2012;76:851–860. doi: 10.1111/j.1365-2265.2011.04191.x.
    1. Spitzer RL, Kroenke K, Williams JBW, Loewe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. Rabin R, Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2009;33:337–343. doi: 10.3109/07853890109002087.
    1. Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Handanweisung. 1. Göttingen: Hogrefe; 1998.
    1. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282:1737–1744. doi: 10.1001/jama.282.18.1737.
    1. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;15:35. doi: 10.1186/1532-429X-15-35.
    1. Wilson PW. Estabilshed risk factors and coronary artery disease: the Framingham study. Am J Hypertens. 1994;7:7–12. doi: 10.1093/ajh/7.7.7S.
    1. Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, et al. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015;33:44–60. doi: 10.1097/HJH.0000000000000415.
    1. Fruchart JC, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109:15–19. doi: 10.1161/01.CIR.0000131513.33892.5b.
    1. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–5602. doi: 10.1210/jc.2003-030871.
    1. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167:311–326. doi: 10.1530/EJE-11-1095.
    1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410–1422. doi: 10.1038/nm.2538.
    1. Neary NM, Booker OJ, Abel BS, Matta JR, Muldoon N, Sinaii N, et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab. 2013;98:2045–2052. doi: 10.1210/jc.2012-3754.
    1. Bayram NA, Ersoy R, Aydin C, Gul K, Keles T, Topaloglu O, et al. Assessment of left ventricular functions by tissue Doppler echocardiography in patients with Cushing’s disease. J Endocrinol Investig. 2009;32:248–252. doi: 10.1007/BF03346461.
    1. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, et al. Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol. 2003;41:2275–2279. doi: 10.1016/S0735-1097(03)00493-5.
    1. Pereira AM, Delgado V, Romijn JA, Smit JWA, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur J Endocrinol. 2010;162:331–340. doi: 10.1530/EJE-09-0621.
    1. Toja PM, Branzi G, Ciambellotti F, Radaelli P, de Martin M, Lonati LM, et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin Endocrinol. 2012;76:332–338. doi: 10.1111/j.1365-2265.2011.04206.x.
    1. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JWA, et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome. Eur J Endocrinol. 2012;166:27–34. doi: 10.1530/EJE-11-0601.
    1. Kamenicky P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, et al. Cardiac structure and function in Cushing’s syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab. 2014;99:2144–2153. doi: 10.1210/jc.2014-1783.
    1. Roux C, Kachenoura N, Raissuni Z, Mousseaux E, Young J, Graves MJ, et al. Effects of cortisol on the heart: characterization of myocardial involvement in Cushing’s disease by longitudinal cardiac MRI T1 mapping. J Magn Reson Imaging. 2017;45:147–156. doi: 10.1002/jmri.25374.
    1. Giordano R, Picu A, Marinazzo E, D'Angelo V, Berardelli R, Karamouzis I, et al. Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol. 2011;75:354–360. doi: 10.1111/j.1365-2265.2011.04055.x.
    1. Barahona MJ, Resmini E, Vilades D, Pons-Llado G, Leta R, Puig T, et al. Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab. 2013;98:1093–1099. doi: 10.1210/jc.2012-3547.
    1. Chandran DS, Ali N, Jaryal AK, Jyotsna VP, Deepak KK. Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing’s syndrome: role of endogenous hypercortisolism. Neuroendocrinology. 2013;97:309–317. doi: 10.1159/000345905.
    1. Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, et al. Specific electrocardiographic features associated with Cushing’s disease. Clin Endocrinol. 2011;74:558–564. doi: 10.1111/j.1365-2265.2011.03975.x.
    1. Hey TM, Dahl JS, Brix TH, Søndergaard EV. Biventricular hypertrophy and heart failure as initial presentation of Cushing’s disease. BMJ Case Rep. 2013;2013:bcr2013201307. doi: 10.1136/bcr-2013-201307.
    1. Berr CM, Stieg MR, Deutschbein T, Quinkler M, Schmidmaier R, Osswald A, et al. Persistence of myopathy in Cushing’s syndrome: evaluation of the German Cushing’s Registry. Eur J Endocrinol. 2017;176:737–746. doi: 10.1530/EJE-16-0689.
    1. Vogel F, Braun LT, Rubinstein G, Zopp S, Künzel H, Strasding F, et al. Persisting muscle dysfunction in cushing's syndrome despite biochemical remission. J Clin Endocrinol Metab. 2020;105(12):e4490–e4498. 10.1210/clinem/dgaa625.
    1. Pecori Giraldi F, Moro M, Cavagnini F. Gender-related differences in the presentation and course of Cushing’s disease. J Clin Endocrinol Metab. 2003;88:1554–1558. doi: 10.1210/jc.2002-021518.
    1. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing’s syndrome after correction of H hypercortisolism. J Clin Endocrinol Metab. 1997;82:912–917.
    1. Santos A, Crespo I, Aulinas A, Resmini E, Valassi E, Webb SM. Quality of life in Cushing’s syndrome. Pituitary. 2015;18:195–200. doi: 10.1007/s11102-015-0640-y.
    1. Webb SM, Santos A, Resmini E, Martínes-Momblán MA, Martel L, Valassi E. Quality of life in Cushing’s disease: a long term issue? Ann Endocrinol. 2018;79:132–137. doi: 10.1016/j.ando.2018.03.007.
    1. Pivonello R, Simeoli C, de Martino MC, Cozzolino A, de Leo M, Lacuaniello D, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci. 2015;9:129. doi: 10.3389/fnins.2015.00129.
    1. Patil CG, Shivanand PL, Katznelson L, Laws ER. Brain atrophy and cognitive deficits in Cushing’s disease. Neurosurg Focus. 2007;23:E11.
    1. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19:269–301.
    1. van Aken MO, Pereira M, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JWA, et al. Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab. 2005;90:3279–3286. doi: 10.1210/jc.2004-1375.
    1. Wagenmakers MAEM, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M, Hermus ARMM. Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur J Endocrinol. 2012;167:687–695. doi: 10.1530/EJE-12-0308.
    1. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006;91:447–453. doi: 10.1210/jc.2005-1058.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel